Supplementary Table S6 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial
<p>Proteomics: DE and Reactome of Cyt proteins</p>
Furkejuvvon:
| Váldodahkki: | |
|---|---|
| Eará dahkkit: | , , , , , , , , , , , , , , , , , , , , , , |
| Almmustuhtton: |
2025
|
| Fáttát: | |
| Fáddágilkorat: |
Lasit fáddágilkoriid
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|
| _version_ | 1849927633209393152 |
|---|---|
| author | Andrés Elía (15055031) |
| author2 | Leo Saldain (15055034) Silvia I. Vanzulli (15055037) Luisa A. Helguero (15055040) Caroline A. Lamb (14947288) Victoria Fabris (15055043) Gabriela Pataccini (15055046) Paula Martínez-Vazquez (15055049) Javier Burruchaga (15055052) Ines Caillet-Bois (15055055) Eunice Spengler (15055058) Gabriela Acosta Haab (15055061) Marcos Liguori (15055064) Alejandra Castets (15055067) Silvia Lovisi (15055070) María F. Abascal (15055073) Virginia Novaro (15055076) Jana Sánchez (15055079) Javier Muñoz (15055082) José M. Belizán (15055085) Martín C. Abba (14947131) Hugo Gass (15055088) Paola Rojas (10737201) Claudia Lanari (14947294) |
| author2_role | author author author author author author author author author author author author author author author author author author author author author author author |
| author_facet | Andrés Elía (15055031) Leo Saldain (15055034) Silvia I. Vanzulli (15055037) Luisa A. Helguero (15055040) Caroline A. Lamb (14947288) Victoria Fabris (15055043) Gabriela Pataccini (15055046) Paula Martínez-Vazquez (15055049) Javier Burruchaga (15055052) Ines Caillet-Bois (15055055) Eunice Spengler (15055058) Gabriela Acosta Haab (15055061) Marcos Liguori (15055064) Alejandra Castets (15055067) Silvia Lovisi (15055070) María F. Abascal (15055073) Virginia Novaro (15055076) Jana Sánchez (15055079) Javier Muñoz (15055082) José M. Belizán (15055085) Martín C. Abba (14947131) Hugo Gass (15055088) Paola Rojas (10737201) Claudia Lanari (14947294) |
| author_role | author |
| dc.creator.none.fl_str_mv | Andrés Elía (15055031) Leo Saldain (15055034) Silvia I. Vanzulli (15055037) Luisa A. Helguero (15055040) Caroline A. Lamb (14947288) Victoria Fabris (15055043) Gabriela Pataccini (15055046) Paula Martínez-Vazquez (15055049) Javier Burruchaga (15055052) Ines Caillet-Bois (15055055) Eunice Spengler (15055058) Gabriela Acosta Haab (15055061) Marcos Liguori (15055064) Alejandra Castets (15055067) Silvia Lovisi (15055070) María F. Abascal (15055073) Virginia Novaro (15055076) Jana Sánchez (15055079) Javier Muñoz (15055082) José M. Belizán (15055085) Martín C. Abba (14947131) Hugo Gass (15055088) Paola Rojas (10737201) Claudia Lanari (14947294) |
| dc.date.none.fl_str_mv | 2025-11-25T13:09:17Z |
| dc.identifier.none.fl_str_mv | 10.1158/1078-0432.30707821 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/dataset/Supplementary_Table_S6_from_Beneficial_Effects_of_Mifepristone_Treatment_in_Patients_with_Breast_Cancer_Selected_by_the_Progesterone_Receptor_Isoform_Ratio_Results_from_the_MIPRA_Trial/30707821 |
| dc.rights.none.fl_str_mv | CC BY info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Cancer Tumor Biology Clinical Research and Trials Breast Cancer Clinical Trial Results Phase II clinical trials Endocrinology Hormone signaling and inhibitors |
| dc.title.none.fl_str_mv | Supplementary Table S6 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial |
| dc.type.none.fl_str_mv | Dataset info:eu-repo/semantics/publishedVersion dataset |
| description | <p>Proteomics: DE and Reactome of Cyt proteins</p> |
| eu_rights_str_mv | openAccess |
| id | Manara_c3f75e3e099b91f8b01d7a55cc5f2c39 |
| identifier_str_mv | 10.1158/1078-0432.30707821 |
| network_acronym_str | Manara |
| network_name_str | ManaraRepo |
| oai_identifier_str | oai:figshare.com:article/30707821 |
| publishDate | 2025 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY |
| spelling | Supplementary Table S6 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA TrialAndrés Elía (15055031)Leo Saldain (15055034)Silvia I. Vanzulli (15055037)Luisa A. Helguero (15055040)Caroline A. Lamb (14947288)Victoria Fabris (15055043)Gabriela Pataccini (15055046)Paula Martínez-Vazquez (15055049)Javier Burruchaga (15055052)Ines Caillet-Bois (15055055)Eunice Spengler (15055058)Gabriela Acosta Haab (15055061)Marcos Liguori (15055064)Alejandra Castets (15055067)Silvia Lovisi (15055070)María F. Abascal (15055073)Virginia Novaro (15055076)Jana Sánchez (15055079)Javier Muñoz (15055082)José M. Belizán (15055085)Martín C. Abba (14947131)Hugo Gass (15055088)Paola Rojas (10737201)Claudia Lanari (14947294)CancerTumor BiologyClinical Research and TrialsBreast CancerClinical Trial ResultsPhase II clinical trialsEndocrinologyHormone signaling and inhibitors<p>Proteomics: DE and Reactome of Cyt proteins</p>2025-11-25T13:09:17ZDatasetinfo:eu-repo/semantics/publishedVersiondataset10.1158/1078-0432.30707821https://figshare.com/articles/dataset/Supplementary_Table_S6_from_Beneficial_Effects_of_Mifepristone_Treatment_in_Patients_with_Breast_Cancer_Selected_by_the_Progesterone_Receptor_Isoform_Ratio_Results_from_the_MIPRA_Trial/30707821CC BYinfo:eu-repo/semantics/openAccessoai:figshare.com:article/307078212025-11-25T13:09:17Z |
| spellingShingle | Supplementary Table S6 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial Andrés Elía (15055031) Cancer Tumor Biology Clinical Research and Trials Breast Cancer Clinical Trial Results Phase II clinical trials Endocrinology Hormone signaling and inhibitors |
| status_str | publishedVersion |
| title | Supplementary Table S6 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial |
| title_full | Supplementary Table S6 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial |
| title_fullStr | Supplementary Table S6 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial |
| title_full_unstemmed | Supplementary Table S6 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial |
| title_short | Supplementary Table S6 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial |
| title_sort | Supplementary Table S6 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial |
| topic | Cancer Tumor Biology Clinical Research and Trials Breast Cancer Clinical Trial Results Phase II clinical trials Endocrinology Hormone signaling and inhibitors |